Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease

Completed · Phase 1

Conditions studied: Chronic Kidney Disease

In brief

The goal of this study is to better understand vitamin D catabolism and how it is affected by CKD and race.

Key facts

Study ID

NCT02937350

Run by

University of Washington

People needed

88

Starts

2017-03-01

Expected to finish

2021-01-01

Last updated by the study team

2021-09-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Self-reported race Caucasian, African American, or African
• Serum total 25(OH)D 10-50 ng/mL
• Estimated GFR:
• 60 mL/min/1.73m2 (N=40) 15-45 mL/min/1.73m2 (N=40) <15 mL/min/1.73m2, treated with hemodialysis (N=40)

You may not qualify if…

• Primary hyperparathyroidism
• Gastric bypass
• Tuberculosis or sarcoidosis
• Current pregnancy
• Child-Pugh Class B or C cirrhosis (i.e. cirrhosis with ascites, hepatic encephalopathy, bilirubin >=2 mg/dL, serum albumin <=3.5 g/dL, or PT >= 4 seconds)
• Use of vitamin D3, or vitamin D2 supplements exceeding a mean daily dose of 400 IU, within 3 months (wash-out allowed)
• Use of 1,25(OH)2D3 or an analogue, calcimimetics, or medications known to induce CYP24A1 within 4 weeks (wash-out allowed)
• Serum calcium > 10.1 mg/dL
• Hemoglobin < 10 g/dL

Where it is running

• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.